Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune cell activating anti-cancer drug products, announced that the Company has been selected to present at the 23rd annual Future Leaders in the Biotech Industry conference hosted by BioCentury. Chief Executive Officer Lewis Bender will present an update on the Company and the development status of INT230-6, an immune cell-activating anti-cancer drug candidate. The presentation will take place at 2:30pm ET on March 11, 2016 in room 402/403 at the Millennium Broadway hotel in New York City, NY.

About INT230-6
INT230-6 is a novel, anticancer drug product able to disperse through tumors and diffuse into cancer cells. The product was identified from Intensity’s DfuseRxSM platform technology. Using in vivo preclinical models of severe cancer, INT230-6 treatment results in substantial improvement in overall survival compared to standard therapies. The product can completely clear large tumors in animal models. Complete responders have long term protection even after multiple re-inoculations of the cancer. INT230-6 administration has shown an increased recruitment of immune cells to the tumor micro-environment.